Drug Discovery

Chemists discover a way to structurally modify vancomycin to make the antibiotic more potent

Assays for PCP, cocaine, opiates, and methamphetamine are due on the market later this year.

Global comparison of genomic contents reveals close relation between E. coli strains that cause traveler's diarrhea.

Company says three triple-combination regimens of its CF next-generation correctors succeed in Phase I and Phase II trials, potentially expanding the universe of CF patients who could benefit from treatment

U.S. Attorney’s Office for the Southern District of New York and FBI allege that the doctors accepted fees for sham educational programs in exchange for prescribing millions of dollars’ worth of Subsys®

4SC Discovery is teaming up with Heidelberg University Hospital and also receiving a $1.79M grant toward development of an ingredient that can target strains of malaria resistant to conventional drugs.

Deal will exploit Ambrx’ biologics optimization technologies, ReCODE™ and EuCODE™. They enable site-selective substitution of novel amino acids.

Firm incurs $455 million charge but will continue developing the antibody for RSV.

Brentuximab vedotin on track for BLA filing with FDA during first half of 2011.

A novel mechanism for the entrapment of misfolded proteins by cargo receptor-containing vesicles suggests a pharmacological strategy for the release of these proteins and their redirection to the lysosome, potentially relieving toxic proteinopathies such as MUC1 kidney disease.